Drug Costs
"Drug Costs" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The amount that a health care institution or organization pays for its drugs. It is one component of the final price that is charged to the consumer (FEES, PHARMACEUTICAL or PRESCRIPTION FEES).
Descriptor ID |
D016527
|
MeSH Number(s) |
N03.219.151.400.350 N05.300.375.300
|
Concept/Terms |
Drug Costs- Drug Costs
- Cost, Drug
- Costs, Drug
- Drug Cost
|
Below are MeSH descriptors whose meaning is more general than "Drug Costs".
Below are MeSH descriptors whose meaning is more specific than "Drug Costs".
This graph shows the total number of publications written about "Drug Costs" by people in UAMS Profiles by year, and whether "Drug Costs" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
2024 | 0 | 1 | 1 | 2023 | 1 | 0 | 1 | 2020 | 0 | 1 | 1 | 2019 | 2 | 1 | 3 | 2017 | 0 | 1 | 1 | 2016 | 0 | 1 | 1 | 2015 | 1 | 1 | 2 | 2014 | 1 | 2 | 3 | 2013 | 1 | 0 | 1 | 2011 | 0 | 2 | 2 | 2007 | 2 | 0 | 2 | 2006 | 0 | 2 | 2 | 2005 | 1 | 1 | 2 | 2003 | 1 | 1 | 2 | 2002 | 1 | 0 | 1 | 2000 | 0 | 1 | 1 | 1996 | 0 | 1 | 1 | 1995 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug Costs" by people in Profiles over the past ten years.
-
Owsley KM, Hasnain-Wynia R, Rooks RN, Tung GJ, Mays GP, Lindrooth RC. US Hospital Service Availability and New 340B Program Participation. JAMA Health Forum. 2024 May 03; 5(5):e240833.
-
Owsley KM, Bradley CJ. Access To Oncology Services In Rural Areas: Influence Of The 340B Drug Pricing Program. Health Aff (Millwood). 2023 06; 42(6):785-794.
-
Collier EK, Price KN, Hsiao JL, Shi VY. Demystifying pharmaceutical patient assistance programs. J Dermatolog Treat. 2022 Feb; 33(1):336-341.
-
Acharya M, Chopra D, Hayes CJ, Teeter B, Martin BC. Cost-Effectiveness of Intranasal Naloxone Distribution to High-Risk Prescription Opioid Users. Value Health. 2020 04; 23(4):451-460.
-
Singh V, Zarrabi AJ, Curseen KA, Sniecinski R, Welsh JW, McKenzie-Brown AM, Baer W, Gillespie TW. Concerns of Patients With Cancer on Accessing Cannabis Products in a State With Restrictive Medical Marijuana Laws: A Survey Study. J Oncol Pract. 2019 10; 15(10):531-538.
-
King J, McAdam-Marx C, McCaleb R, Davis D, Bemberg GB, Johnson JT. Cost and Utilization Outcomes After Exclusion of Dipeptidyl Peptidase-4 Inhibitors and Other Diabetes Drug Category Changes in a Self-Funded, State Employee Managed Care Plan. J Manag Care Spec Pharm. 2019 Jun; 25(6):646-651.
-
Feinstein JA, Hall M, Antoon JW, Thomson J, Flores JC, Goodman DM, Cohen E, Azuine R, Agrawal R, Houtrow AJ, DeCourcey DD, Kuo DZ, Coller R, Gaur DS, Berry JG. Chronic Medication Use in Children Insured by Medicaid: A Multistate Retrospective Cohort Study. Pediatrics. 2019 04; 143(4).
-
Helm ME. Value-Based Insurance Design Pharmacy Benefits for Children and Youth With Special Health Care Needs: Principles and Opportunities. Pediatrics. 2017 May; 139(Suppl 2):S117-S126.
-
Wen H, Borders TF, Druss BG. Number Of Medicaid Prescriptions Grew, Drug Spending Was Steady In Medicaid Expansion States. Health Aff (Millwood). 2016 09 01; 35(9):1604-7.
-
Pang WK, Yeter KC, Torralba KD, Spencer HJ, Khan NA. Financial conflicts of interest and their association with outcome and quality of fibromyalgia drug therapy randomized controlled trials. Int J Rheum Dis. 2015 Jul; 18(6):606-15.
-
Beebe A, Quattlebaum T, Gicquelais RE, Zohoori N, Haselow DT, Smith NH, Patil N. Hepatitis C in Arkansas: updates on epidemiology, testing and treatment. J Ark Med Soc. 2015 May; 111(12):248-51.
|
People People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|